In neurology, particularly in stroke prevention, these devices are pivotal in assessing platelet function and tailoring antiplatelet therapies. The personalized approach to antiplatelet therapy guided by platelet aggregation testing contributes to a more nuanced and effective management of patients at risk of cerebrovascular events. Likewise, the intersection of these devices with oncology involves evaluating the thrombotic risk in cancer patients. Platelet function testing assists in identifying individuals at higher risk of venous thromboembolism, contributing to prophylactic measures and personalized anticoagulant therapy in the oncology setting.
Furthermore, one prominent trend in the market is the integration of automation and robotics. Automated devices streamline testing processes, enhance reproducibility, and minimize variability, contributing to more reliable and efficient platelet function assessments. Robotics further elevate precision and throughput, setting the stage for future advancements. Continuous advancements in sensor technologies and detection methods are shaping the landscape of these devices. Innovations in optical sensors, impedance-based technologies, and real-time monitoring contribute to enhanced sensitivity, accuracy, and the ability to capture dynamic platelet responses.
The rising prominence of research and academic institutes in the United States significantly impacted the market. The devices became integral components of research laboratories, hematology departments, and medical schools, contributing to a broader understanding of platelet function and related disorders. Furthermore, the Canadian government has consistently invested in its healthcare system, contributing to developing and modernizing healthcare infrastructure. Funding initiatives to improve diagnostic capabilities have facilitated the adoption of advanced medical devices, including these devices. Thus, growing research and academic institutes and the healthcare sector in North America will assist in the growth of the regional market.
The US market dominated the North America Platelet Aggregation Devices Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $288.2 Million by 2030. The Canada market is experiencing a CAGR of 7.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 6.2% during (2023 - 2030).
Based on Product, the market is segmented into Consumables & Accessories, and Systems & Instruments. Based on End-Use, the market is segmented into Research & Academic Institutes, Hospital, and Diagnostic Centers. Based on Application, the market is segmented into Research, and Clinical. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- AggreDyne, Inc.
- Bio/Data Corporation
- Chrono-log Corporation
- F.Hoffmann-La Roche Ltd.
- Haemonetics Corporation
- Siemens Healthineers AG (Siemens AG)
- Werfen, S.A.
- Sysmex Corporation
- Sienco, Inc.
Market Report Segmentation
By Product- Consumables & Accessories
- Systems & Instruments
- Research & Academic Institutes
- Hospital
- Diagnostic Centers
- Research
- Clinical
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Companies Mentioned
- AggreDyne, Inc.
- Bio/Data Corporation
- Chrono-log Corporation
- F. Hoffmann-La Roche Ltd.
- Haemonetics Corporation
- Siemens Healthineers AG (Siemens AG)
- Werfen, S.A.
- Sysmex Corporation
- Sienco, Inc.
Methodology
LOADING...